Literature DB >> 21780125

REGIV as a potential biomarker for peritoneal dissemination in gastric adenocarcinoma.

Jeong-Ho Moon1, Yoshiyuki Fujiwara, Yurika Nakamura, Kaoru Okada, Hiroyuki Hanada, Chohei Sakakura, Shuji Takiguchi, Kiyokazu Nakajima, Hiroshi Miyata, Makoto Yamasaki, Yukinori Kurokawa, Masaki Mori, Yuichiro Doki.   

Abstract

BACKGROUND: This study examined the clinical significance of regenerating islet-derived family member 4 (REGIV) in surgically resected gastric tumors. The potential of REGIV as a biomarker in gastric cancer was also assessed including its predictive value for prognosis and recurrence after surgery.
METHODS: Immunohistochemistry was performed to assess the clinical significance of REGIV expression status in surgically resected specimens. The quantitative genetic diagnostic method, transcription-reverse transcription concerted reaction (TRC) that targeted REGIV mRNA was applied for prediction of peritoneal recurrence in gastric cancer.
RESULTS: Positive immunostaining for REGIV was observed in 85 cases (52.5%), and correlated significantly with diffuse type histopathology (P = 0.001), advanced T stage (P = 0.022), and frequent peritoneal recurrence (P = 0.009). Multivariate analysis identified advanced T stage (P < 0.001) and REGIV expression (P = 0.034) as independent prognostic factors for peritoneal recurrence-free survival. Overexpression of REGIV protein was evident in the majority of peritoneal tumors (93.8%). REGIV mRNA assessed by TRC could be a predictive marker for peritoneal recurrence after curative operation.
CONCLUSIONS: REGIV overexpression is common in primary gastric tumors and a potentially suitable marker of diffuse type histopathology and peritoneal dissemination. Overexpression of REGIV mRNA, assessed by the TRC method, is a potentially suitable marker of peritoneal recurrence after curative resection.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21780125     DOI: 10.1002/jso.22021

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  9 in total

1.  REG4 is an indicator for KRAS mutant lung adenocarcinoma with TTF-1 low expression.

Authors:  Si Sun; Zhihuang Hu; Shenglin Huang; Xun Ye; Jialei Wang; Jianhua Chang; Xianghua Wu; Qifeng Wang; Lanlin Zhang; Xingjiang Hu; Hui Yu
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-19       Impact factor: 4.553

2.  An integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer.

Authors:  Qing-Wen Xu; Wei Zhao; Yue Wang; Maureen A Sartor; Dong-Mei Han; Jixin Deng; Rakesh Ponnala; Jiang-Ying Yang; Qing-Yun Zhang; Guo-Qing Liao; Yi-Mei Qu; Lu Li; Fang-Fang Liu; Hong-Mei Zhao; Yan-Hui Yin; Wei-Feng Chen; Yu Zhang; Xiao-Song Wang
Journal:  Cancer Res       Date:  2012-11-07       Impact factor: 12.701

3.  Reg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ductal adenocarcinoma.

Authors:  Qing Li; Hao Wang; George Zogopoulos; Qin Shao; Kun Dong; Fudong Lv; Karam Nwilati; Xian-Yong Gui; Adeline Cuggia; Jun-Li Liu; Zu-Hua Gao
Journal:  Oncotarget       Date:  2016-11-22

Review 4.  REG4 promotes the proliferation and anti-apoptosis of cancer.

Authors:  Hua-Chuan Zheng; Hang Xue; Cong-Yu Zhang
Journal:  Front Cell Dev Biol       Date:  2022-09-12

5.  Epstein-barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profile.

Authors:  Weihua Tang; Douglas R Morgan; Michael O Meyers; Ricardo L Dominguez; Enrique Martinez; Kennichi Kakudo; Pei Fen Kuan; Natalie Banet; Hind Muallem; Kimberly Woodward; Olga Speck; Margaret L Gulley
Journal:  Infect Agent Cancer       Date:  2012-08-28       Impact factor: 2.965

6.  In vivo targeting of ADAM9 gene expression using lentivirus-delivered shRNA suppresses prostate cancer growth by regulating REG4 dependent cell cycle progression.

Authors:  Che-Ming Liu; Chia-Ling Hsieh; Yun-Chi He; Sen-Jei Lo; Ji-An Liang; Teng-Fu Hsieh; Sajni Josson; Leland W K Chung; Mien-Chie Hung; Shian-Ying Sung
Journal:  PLoS One       Date:  2013-01-16       Impact factor: 3.240

7.  Tumor suppressor miR-24 restrains gastric cancer progression by downregulating RegIV.

Authors:  Yantao Duan; Lei Hu; Bing Liu; Beiqin Yu; Jianfang Li; Min Yan; Yingyan Yu; Chen Li; Liping Su; Zhenggang Zhu; Ming Xiang; Bingya Liu; Qiumeng Yang
Journal:  Mol Cancer       Date:  2014-05-28       Impact factor: 27.401

8.  REG4 promotes peritoneal metastasis of gastric cancer through GPR37.

Authors:  Hexiao Wang; Lei Hu; Mingde Zang; Baogui Zhang; Yantao Duan; Zhiyuan Fan; Jianfang Li; Liping Su; Min Yan; Zhenggang Zhu; Bingya Liu; Qiumeng Yang
Journal:  Oncotarget       Date:  2016-05-10

9.  Expression of Reg IV and SOX9 and their correlation in human gastric cancer.

Authors:  Na Zhang; Dandan Chai; Huifen Du; Kesheng Li; Wenguang Xie; Xingwen Li; Rong Yang; Xiaowen Lian; Yang Xu
Journal:  BMC Cancer       Date:  2018-03-27       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.